Program
Emtricitabine
Also written as “E/C/F/TAF”, “B/F/TAF” and “F/TAF”.
Its studies are mostly in HIV Infections · Acquired Immunodeficiency Syndrome · Coinfection · Kidney Failure, Chronic · Hepatitis C, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciences | 427 open or running | phase 4since Mar 23, 2005 | Mar 23, 2005 | Jun 2027phase 4 · NCT06337032 |
| Triangle Pharmaceuticals | 30 open or running | phase 3since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| GlaxoSmithKline | 20 open or running | phase 1since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Laboratorio Elea Phoenix | 20 open or running | phase 4since Oct 10, 2017 | Oct 19, 2015 | none ahead |
| The Crofoot Research Center | 10 open or running | phase 4since May 12, 2020 | May 12, 2020 | none ahead |
Also a collaborator on its studies: Merck, Johnson & Johnson and Bristol-Myers Squibb.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 36 studies since Nov 2, 1999.
- Jan 12, 2018Phase 3 study in HIV-1 InfectionGilead Sciences · NCT03405935 · 86 enrolled · Belgium, France, Italy and more
- May 24, 2018Phase 3 study in HIV-1/HBV Co-InfectionGilead Sciences · NCT03547908 · 244 enrolled · United States, China, Dominican Republic and more
- Aug 13, 2018Phase 3 study in HIV-1 InfectionGilead Sciences · NCT03631732 · 496 enrolled · United States
- Feb 7, 2019Phase 1 study in HIV InfectionsGlaxoSmithKline · NCT03836729 · 16 enrolled · United States
- May 21, 2019Phase 1 study in HIV-1-infectionGilead Sciences · NCT03960645 · 62 enrolled · United States, Dominican Republic, Thailand
- Oct 28, 2019Phase 2 study in HIV-1-infectionGilead Sciences · NCT04143594 · 183 enrolled · United States, Dominican Republic, Puerto Rico
- May 12, 2020The Crofoot Research Center's first study: phase 4 study in Acquired Immunodeficiency SyndromeNew to The Crofoot Research CenterThe Crofoot Research Center · NCT04388904 · 75 enrolled · United States
- Aug 2, 2021Phase 3 study in Pre-Exposure Prophylaxis of HIV InfectionGilead Sciences · NCT04994509 · 5,368 enrolled · South Africa, Uganda
- Oct 23, 2023Phase 4 study in HIV-1-infectionGilead Sciences · NCT06104306 · 33 enrolled · United States, Canada, France
- Mar 22, 2024Phase 4 study in HIV-1-infectionGilead Sciences · NCT06337032 · 350 planned · Argentina, Panama, South Africa and more
- Oct 4, 2024Phase 3 study in HIV-1-infectionGilead Sciences · NCT06630286 · 609 enrolled · United States, Argentina, Australia and more
- Jun 27, 2025Phase 1 study in HIV-1-infectionGilead Sciences · NCT07055451 · 16 enrolled · United States, South Africa
- Jun 8, 2026Phase 2 study in HIV-1-infectionGilead Sciences · NCT07645287 · 175 planned · United States, Australia, Canada and more
- Jul 13, 2026Phase 3 study in HIV-1-infectionGilead Sciences · NCT07708727 · 700 planned · United States, Canada, Germany and more
Ahead
- Jun 2027Primary completion: phase 4 study in HIV-1-infectionGilead Sciences · NCT06337032
- Aug 2027Primary completion: phase 2 study in HIV-1-infectionGilead Sciences · NCT07645287
- Mar 2028Primary completion: phase 1 study in HIV-1-infectionGilead Sciences · NCT07055451
- Oct 2030Primary completion: phase 3 study in HIV-1-infectionGilead Sciences · NCT07708727
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Human immunodeficiency virus type 1 reverse transcriptase inhibitor”ChEMBL 37, by rule
Studies
All 50 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07708727HIV-1-infection · United States, Canada, Germany and more | 3 | Recruiting | Gilead Sciences | Oct 2030 | 700 |
| NCT07645287HIV-1-infection · United States, Australia, Canada and more | 2 | Recruiting | Gilead Sciences | Aug 2027 | 175 |
| NCT07055451HIV-1-infection · United States, South Africa | 1 | Active, not recruiting | Gilead Sciences | Mar 2028 | 16 |
| NCT06630286HIV-1-infection · United States, Argentina, Australia and more | 3 | Active, not recruiting | Gilead Sciences | Apr 17, 2026 | 609 |
| NCT06337032HIV-1-infection · Argentina, Panama, South Africa and more | 4 | Recruiting | Gilead Sciences | Jun 2027 | 350 |
| NCT06104306HIV-1-infection · United States, Canada, France | 4 | Completed | Gilead Sciences | Jan 29, 2025 | 33 |
| NCT04994509Pre-Exposure Prophylaxis of HIV Infection · South Africa, Uganda | 3 | Active, not recruiting | Gilead Sciences | May 27, 2024 | 5,368 |
| NCT04388904Acquired Immunodeficiency Syndrome · United States | 4 | Completed | The Crofoot Research Center | Apr 5, 2024 | 75 |
| NCT04143594HIV-1-infection · United States, Dominican Republic, Puerto Rico | 2 | Completed | Gilead Sciences | Oct 5, 2021 | 183 |
| NCT03960645HIV-1-infection · United States, Dominican Republic, Thailand | 1 | Completed | Gilead Sciences | Jul 21, 2022 | 62 |
| NCT03836729HIV Infections · United States | 1 | Completed | GlaxoSmithKline | Mar 30, 2019 | 16 |
| NCT03631732HIV-1 Infection · United States | 3 | Completed | Gilead Sciences | Aug 12, 2019 | 496 |
| NCT03547908HIV-1/HBV Co-Infection · United States, China, Dominican Republic and more | 3 | Completed | Gilead Sciences | Feb 25, 2022 | 244 |
| NCT03405935HIV-1 Infection · Belgium, France, Italy and more | 3 | Completed | Gilead Sciences | Nov 20, 2018 | 86 |
| NCT03309566Healthy · Argentina | 4 | Completed | Laboratorio Elea Phoenix | Feb 28, 2017 | 24 |
| NCT03110380HIV-1-infection · United States, Austria, Canada and more | 3 | Completed | Gilead Sciences | Dec 4, 2018 | 567 |
| NCT02842086Pre-Exposure Prophylaxis of HIV-1 Infection · United States, Austria, Canada and more | 3 | Terminated | Gilead Sciences | Jan 31, 2019 | 5,399 |
| NCT02707601Hepatitis C · United States, Puerto Rico | 3 | Completed | Gilead Sciences | Sep 14, 2017 | 150 |
| NCT02652624HIV-1 Infection · United States, Dominican Republic, Puerto Rico and more | 3 | Completed | Gilead Sciences | Oct 9, 2017 | 472 |
| NCT02616029HIV-1 Infection · United States, France, Germany and more | 3 | Completed | Gilead Sciences | Oct 11, 2018 | 66 |
| NCT02616783HIV-1 Infection · Belgium, France, Italy and more | 3 | Completed | Gilead Sciences | Feb 21, 2018 | 167 |
| NCT02605954HIV-1 Infection · United States, France, Germany and more | 3 | Completed | Gilead Sciences | Jun 14, 2017 | 275 |
| NCT02607956HIV-1 Infection · United States, Australia, Belgium and more | 3 | Completed | Gilead Sciences | May 12, 2017 | 657 |
| NCT02600819Kidney Failure, Chronic · United States, Austria, France and more | 3 | Completed | Gilead Sciences | Sep 29, 2017 | 55 |
| NCT02583464Acquired Immunodeficiency Syndrome · Argentina | 1 | Completed | Laboratorio Elea Phoenix | Oct 2014 | 24 |
| NCT02469246HIV-1 Infection · United States, Belgium, Canada and more | 3 | Completed | Gilead Sciences | Dec 11, 2017 | 567 |
| NCT02397694HIV-1 Infection · United States | 2 | Completed | Gilead Sciences | Nov 30, 2015 | 98 |
| NCT02276612HIV · United States, South Africa | 3 | Completed | Gilead Sciences | Nov 10, 2016 | 60 |
| NCT02121795HIV-1 Infection · United States, Belgium, Canada and more | 3 | Completed | Gilead Sciences | Aug 12, 2015 | 668 |
| NCT02071082Coinfection · United States, Canada, Japan | 3 | Completed | Gilead Sciences | Jan 23, 2015 | 79 |
| NCT02016924Acquired Immunodeficiency Syndrome · United States, Argentina, South Africa and more | 3 | Active, not recruiting | Gilead Sciences | Jun 13, 2025 | 133 |
| NCT01967940HIV Infections · United States, Dominican Republic, Russian Federation and more | 3 | Completed | Gilead Sciences | May 21, 2015 | 55 |
| NCT01968551HIV Infections · United States, Canada | 3 | Completed | Gilead Sciences | Jul 21, 2015 | 158 |
| NCT01854775Acquired Immunodeficiency Syndrome · United States, South Africa, Thailand and more | 3 | Completed | Gilead Sciences | May 11, 2020 | 129 |
| NCT01818596HIV Infections · United States, Australia, Dominican Republic and more | 3 | Completed | Gilead Sciences | Jul 31, 2014 | 252 |
| NCT01815736HIV Infections · United States, Australia, Austria and more | 3 | Completed | Gilead Sciences | Mar 16, 2015 | 1,443 |
| NCT01797445HIV Infections · United States, Canada, Dominican Republic and more | 3 | Completed | Gilead Sciences | Sep 19, 2014 | 872 |
| NCT01780506HIV Infections · United States, Australia, Austria and more | 3 | Completed | Gilead Sciences | Aug 26, 2014 | 872 |
| NCT00743340HIV-1 Infection · South Africa | 2 | Completed | Gilead Sciences | Feb 13, 2017 | 50 |
| NCT00642291HIV Infections · Romania | 2 | Completed | Gilead Sciences | Jul 2004 | 16 |
| NCT00615745HIV Infections · United Kingdom | 4 | Completed | Gilead Sciences | Nov 2010 | 115 |
| NCT00365612HIV Infections · United States, Puerto Rico | 4 | Completed | Gilead Sciences | Oct 2007 | 300 |
| NCT00362687HIV Infections · Spain | 4 | Completed | Gilead Sciences | May 2008 | 50 |
| NCT00307489Hepatitis B, Chronic · United States, France, Germany and more | 2 | Completed | Gilead Sciences | Jan 2008 | 106 |
| NCT00112047HIV Infections · United States | 3 | Completed | Gilead Sciences | Feb 2005 | 517 |
| NCT00106379HIV Infections · United States | 4 | Completed | Gilead Sciences | 52 | |
| NCT00017992HIV Infections · United States, Argentina, Mexico and more | 2 | UNKNOWN | Triangle Pharmaceuticals | 100 | |
| NCT00006208HIV Infections · United States, Argentina, Canada and more | 3 | UNKNOWN | Triangle Pharmaceuticals | ||
| NCT00002362HIV Infections · United States | 3 | Suspended | Triangle Pharmaceuticals | ||
| NCT00002335HIV Infections · United States | 1 | Completed | GlaxoSmithKline | 18 |
How it is read
Names in the registry
- “E/C/F/TAF”, 16 entries
- “B/F/TAF”, 10 entries
- “Emtricitabine”, 9 entries
- “F/TAF”, 8 entries
- “Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC”, 3 entries
Conditions, from the studies’ own filings
- HIV Infections, 18 studies
- Acquired Immunodeficiency Syndrome, 9 studies
- Coinfection, 2 studies
- Kidney Failure, Chronic, 1 study
- Hepatitis C, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.